Continued development of azithromycin as a neuroprotective therapeutic for the treatment of spinal cord injury and other neurological conditions
Timothy J. Kopper
John C. Gensel
1.Spinal Cord and Brain Injury Research Center, Department of Physiology, University of Kentucky, Lexington, KY, USA2.Spinal Cord and Brain Injury Research Center, Department of Physiology, University of Kentucky, Lexington, KY, USA
摘要：Spinal cord injury (SCI) induces a robust inflammatory response largely mediated by resident microglia and infiltrating macrophages across the blood-brain barrier. While these cell populations are capable of promoting repair and regenerative responses, in the days and weeks after SCI they predominately adopt pro-inflammatory profiles known to inhibit recovery and potentiate secondary injury pathways. Continued work is needed to develop clinically viable immunomodulatory therapeutics and promote pro-reparative macrophage responses. Recently we published on the therapeutic benefits of the macrolide antibiotic azithromycin (AZM), which improves locomotor and histological recovery after SCI in 3-month-old female mice (Kopper et al., 2019).
机标关键词：
论文发表日期：2021-03-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：2( 508-509 )